Posted: August 14, 2022 at 2:33 am
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023
Here is the original post:
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Posted: August 14, 2022 at 2:33 am
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.
See the rest here:
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
Posted: August 14, 2022 at 2:33 am
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022
Posted: August 14, 2022 at 2:33 am
CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.
Original post:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
Posted: August 14, 2022 at 2:33 am
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release
View post:
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Posted: August 14, 2022 at 2:33 am
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval
Posted: August 14, 2022 at 2:33 am
Conference call begins at 11:00 a.m. Eastern time today
Read the original:
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Posted: August 14, 2022 at 2:33 am
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.
View original post here:
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Posted: August 14, 2022 at 2:33 am
REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.
Originally posted here:
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Posted: August 14, 2022 at 2:33 am
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -
Original post:
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
